Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

Rhea-AI Summary

Autonomix (NASDAQ: AMIX) announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,369,852 on October 9, 2025 for "Controlled and Precise Treatment of Cardiac Tissues."

The '852 patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and deliver therapy with closed-loop feedback for precision neuromodulation, denervation, and ablation of cardiac tissues. The filing is described as adding to a global IP portfolio of over 120 issued and pending patent applications and is positioned to address indications including arrhythmias, refractory angina, heart failure, hypertension, and plaque/inflammation modulation.

Positive

• USPTO issued U.S. Patent No. 12,369,852 on Oct 9, 2025
• Company reports a global IP portfolio of over 120 issued and pending patents
• Patent claims closed-loop sensing and therapy for precision cardiac neuromodulation

Negative

• None.

Insights

IP strategy expert

USPTO granted U.S. Patent No. 12,369,852 on precision cardiac nerve-targeted therapy; strengthens Autonomix's IP position.

Autonomix Medical, Inc. secured U.S. Patent No. 12,369,852 on Oct. 09, 2025, which covers systems that sense autonomic/cardiac signals, map neural targets, and deliver closed-loop feedback therapies such as neuromodulation, denervation, and ablation to cardiac tissues. The claim set, as described, spans sensing, mapping, and feedback-driven delivery and therefore broadens the company’s asserted control over a platform designed to enable multiple cardiac applications.

The practical value depends on claim scope, enforceability, and remaining prosecution in other jurisdictions; patent issuance alone does not confirm commercial adoption or regulatory clearance. Key dependencies include the strength of the claims against competing approaches, pending or issued family patents internationally, and the company’s ability to pair IP with clinical evidence and regulatory approvals to monetize the platform.

Watch for three concrete developments over the next 12–36 months: publication of claim language and independent claim breadth, corresponding filings/grants outside the U.S., and any clinical/regulatory milestones that enable commercial use. These items will determine whether the granted patent translates into defensible market advantage or remains strategic token protection.

 With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation

Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases

THE WOODLANDS, TX, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,369,852 (the ‘852 patent), titled, “Controlled and Precise Treatment of Cardiac Tissues.” The newly issued ‘852 patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and then deliver therapy with closed-loop feedback to precisely treat cardiac tissues by performing feedback-driven neuromodulation, denervation, and/or ablation of tissues.

“We are pleased to further reinforce our intellectual property around our technology. The autonomic nervous system plays a major role in regulating and maintaining normal cardiac activity. Cardiac disease is often treated by sympathetic beta-receptor blockade, which affects all cells and organs of the body and often leads to unwanted and intolerable side effects. Our breakthrough technology has the potential to provide precision nerve-targeted therapies that could transform treatment in high-growth areas of cardiology, including renal denervation for hypertension, arrhythmia management, heart failure, and refractory angina, offering new solutions with fewer complications,” commented Brad Hauser, CEO of Autonomix.

In particular, the ‘852 patent relates to systems, devices, and methods for performing precise treatment, mapping, and/or testing of tissues and for identifying, localizing, monitoring, and mapping neural traffic near targeted regions. Further, the patent highlights applications across arrhythmias (atrial & ventricular), ischemia/angina (including refractory angina pain), coronary spasm, myocardial infarction risk modulation, heart failure, hypertension (including interplay with renal-cardiac nerves), and plaque/inflammation modulation, where local, feedback-guided denervation or modulation may reduce dependence on systemic beta blockade and its side effects.

Autonomix’s first-in-class technology constitutes a platform with the potential to address dozens of indications in multiple high-need therapeutic areas, including cardiology and resistant hypertension or high blood pressure, interventional pain management, pulmonary and gastrointestinal disorders, and more. For more information about the Company’s technology, please visit autonomix.com.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

FAQ

What did Autonomix (AMIX) announce on October 9, 2025?

Autonomix announced the issuance of U.S. Patent No. 12,369,852 for controlled and precise treatment of cardiac tissues.

What does U.S. Patent No. 12,369,852 cover for AMIX?

The patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and deliver closed-loop feedback therapy for neuromodulation, denervation, and ablation.

How large is Autonomix's patent portfolio after the new patent?

Autonomix reports a global intellectual property portfolio of over 120 issued and pending patent applications.

Which cardiology conditions does the AMIX patent highlight?

The patent highlights applications across arrhythmias, refractory angina, heart failure, hypertension, and plaque/inflammation modulation.

Will the AMIX patent affect current systemic beta-blocker treatment?

The company suggests the technology could enable local, feedback-guided denervation or modulation that may reduce dependence on systemic beta blockade and its side effects.

Where can investors find more information about Autonomix technology and IP?

Investors can visit autonomix.com for additional information about the company's technology and patent portfolio.